MX2020013699A - Derivados de pirazol como inhibidores de malt1. - Google Patents

Derivados de pirazol como inhibidores de malt1.

Info

Publication number
MX2020013699A
MX2020013699A MX2020013699A MX2020013699A MX2020013699A MX 2020013699 A MX2020013699 A MX 2020013699A MX 2020013699 A MX2020013699 A MX 2020013699A MX 2020013699 A MX2020013699 A MX 2020013699A MX 2020013699 A MX2020013699 A MX 2020013699A
Authority
MX
Mexico
Prior art keywords
sub
pyrazole derivatives
malt1 inhibitors
malt1
inhibitors
Prior art date
Application number
MX2020013699A
Other languages
English (en)
Inventor
Gaston Stanislas Marcella Diels
Tongfei Wu
James Patrick Edwards
Tianbao Lu
Peter J Connolly
Ulrike Philippar
Maxwell David Cummings
Jan Willem Thuring
Didier Jean- Claude BERTHELOT
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020013699A publication Critical patent/MX2020013699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos, composiciones y métodos para tratar enfermedades, síndromes, afecciones o trastornos que son afectados por la modulación de MALT1; tales compuestos se representan mediante la Fórmula (I) como sigue: en donde R1, R2, 5 R3, R4, R5, R6, R7, G1 y G2 se definen en la presente descripción.
MX2020013699A 2018-06-18 2019-06-13 Derivados de pirazol como inhibidores de malt1. MX2020013699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862686451P 2018-06-18 2018-06-18
PCT/IB2019/054965 WO2019243965A1 (en) 2018-06-18 2019-06-13 Pyrazole derivatives as malt1 inhibitors

Publications (1)

Publication Number Publication Date
MX2020013699A true MX2020013699A (es) 2021-05-12

Family

ID=67688806

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013699A MX2020013699A (es) 2018-06-18 2019-06-13 Derivados de pirazol como inhibidores de malt1.

Country Status (13)

Country Link
US (1) US10888550B2 (es)
EP (1) EP3810609B1 (es)
JP (1) JP7296407B2 (es)
KR (1) KR20210024002A (es)
CN (1) CN112601747B (es)
AU (1) AU2019289223B2 (es)
BR (1) BR112020025814A2 (es)
CA (1) CA3104055A1 (es)
EA (1) EA202092962A1 (es)
IL (1) IL279452B (es)
MX (1) MX2020013699A (es)
PH (1) PH12020552206A1 (es)
WO (1) WO2019243965A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040031B2 (en) * 2018-06-18 2021-06-22 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
KR20210151880A (ko) * 2019-04-11 2021-12-14 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피리딘 고리 함유 유도체
CN117120427A (zh) * 2021-06-18 2023-11-24 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途
WO2023125877A1 (zh) * 2021-12-30 2023-07-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
ATE455104T1 (de) 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
EP2385041B1 (en) 2003-05-01 2013-09-18 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
CA2657660A1 (en) 2006-07-12 2008-01-17 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
AU2009295936B2 (en) 2008-09-24 2014-07-17 Basf Se Pyrazole compounds for controlling invertebrate pests
PT3149001T (pt) * 2014-05-28 2019-07-25 Novartis Ag Novos derivados de pirazolee pirimidina e seu uso como inibidores de malt1
CA2960574C (en) * 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Pyrazolopyrimidine derivatives as nik inhibitors
CN108064224B (zh) * 2014-10-30 2022-03-29 詹森药业有限公司 作为Rorγt的调节剂的酰胺取代的噻唑
WO2017040304A1 (en) * 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
WO2017057695A1 (ja) * 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
KR20180080311A (ko) * 2015-11-13 2018-07-11 노파르티스 아게 신규 피라졸로 피리미딘 유도체
SG11201900745VA (en) * 2016-07-29 2019-02-27 Lupin Ltd Substituted thiazolo-pyridine compounds as malt1 inhibitors
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物

Also Published As

Publication number Publication date
KR20210024002A (ko) 2021-03-04
CA3104055A1 (en) 2019-12-26
US10888550B2 (en) 2021-01-12
WO2019243965A1 (en) 2019-12-26
EP3810609B1 (en) 2024-06-12
IL279452A (en) 2021-01-31
BR112020025814A2 (pt) 2021-04-06
EP3810609A1 (en) 2021-04-28
JP2021528401A (ja) 2021-10-21
US20190381012A1 (en) 2019-12-19
IL279452B (en) 2022-06-01
CN112601747B (zh) 2023-02-21
CN112601747A (zh) 2021-04-02
AU2019289223B2 (en) 2023-09-21
AU2019289223A1 (en) 2021-01-07
JP7296407B2 (ja) 2023-06-22
EA202092962A1 (ru) 2021-09-06
PH12020552206A1 (en) 2021-06-28

Similar Documents

Publication Publication Date Title
TN2019000192A1 (en) Pyrazole derivatives as malt1 inhibitors
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
PH12021500014A1 (en) Fused ring compounds
PH12021551065A1 (en) Fused ring compounds
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
MX2020007265A (es) Derivados de rapamicina.
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
MX2021012706A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MX2022003166A (es) Moduladores de il-17a y usos de los mismos.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
PH12021550743A1 (en) Boron containing pde4 inhibitors
MX2023013445A (es) Compuestos heterociclicos sustituidos.
MX2023005928A (es) Moduladores de malt-1.
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
MX2021012417A (es) Anillos de piridina que contienen derivados como inhibidores de malt1.
MX2022002443A (es) Compuestos inhibidores de perk.
MX2021014580A (es) Derivados heterociclos condensados como moduladores de ensamblaje de la capside.